Você procurou por: behandlingsfordele (Dinamarquês - Inglês)

behandlingsfordele
treatment benefits

opfattelsen af behandlingsfordele blev målt ved patient global impression of change (pgic) spørgeskema.
treatment benefit perception was measured by the patient global impression of change (pgic) questionnaire.

ariclaim bør kun bruges under graviditeten, hvis de potentielle behandlingsfordele opvejer de potentielle risici for fosteret.
ariclaim should be used in pregnancy only if the potential benefit justifies the potential risk to the foetus.

duloxetine boehringer ingelheim bør kun bruges under graviditeten, hvis de potentielle behandlingsfordele opvejer de potentielle risici for fosteret.
duloxetine boehringer ingelheim should be used in pregnancy only if the potential benefit justifies the potential risk to the foetus.

disse udgifter er imidlertid marginale sammenlignet med de øgede behandlingsfordele, der også vokser i takt med de øgede muligheder for at gøre brug af sundhedsydelser i udlandet.
these costs remain nevertheless marginal compared to the increased treatment benefits, which also increase with the increase of possibilities to receive healthcare abroad.

forbedringer i opfattelsen af behandlingsfordele ved uge 32 var også højere hos patienter behandlet med ruxolitinib (78% mod 33%).
improvement in perception of treatment benefit was also higher in patients treated with ruxolitinib at week 32 (78% versus 33%).

0,3 mg pegaptanib viser behandlingsfordele uanset baseline læsionsundergruppe, læsionsstørrelse og synsskarphed såvel som alder, køn, irispigmentering og tidligere og/eller baseline pdt behandling.
pegaptanib 0.3 mg showed treatment benefit regardless of baseline lesion subtype, lesion size and visual acuity as well as age, gender, iris pigmentation and prior and/or baseline pdt usage.

der blev dog påvist en signifikant behandlingsfordel for celsentri sammenlignet med ob alene (se tabel 8).
however, a significant treatment benefit for celsentri compared to obt alone was still demonstrated (see table 8).